Table 4.
Curcumin examined for possible effects on animal models of malaria.
| Mouse | Treatment schedule |
Treatment effect | Ref. | ||
|---|---|---|---|---|---|
| Dose | Days p.i. | Method | |||
| Albino mice (P. berghei ANKA) | Curcuminoids liposomes 10 mg/kg 20 mg/kg 40 mg/kg |
0–3 | IV | For 10–20 mg/kg group, 60–70% parasitemia on day 6, died by 7–8 days. For 40 mg/kg group, suppressed parasitemia up to 9 days and prolonged survival up to 11 days. |
112 |
| Swiss mice (P. berghei ANKA) | Curcumin 100 mg/kg for 5 days | 0–2 | Oral | Curcumin treatment resulted in overall survival rate of 29% compared to 0% in vehicle fed animals 21 days p.i., decreased blood parasitemia by 80–90%. | 96 |
| Swiss mice (P. yoelli) | Curcumin loaded chitosan nanoparticles 33.33 mg/kg | 3–10 | Oral | Curcumin bound chitosan nanoparticles prolonged survival up to 15 days p.i. in comparison to day 9 of p.i. in control mice. Curcumin alone lead to survival of 33% mice whereas group treated with curcumin nanoparticle showed 100% survival. |
113 |
| Albino mice (P. berghei) | Curcuminoid loaded SLN, NLC 100 mg/kg | – | IP | Mice treated with drug loaded SLN and NLC showed significantly 2 fold longer survival as compared to control and free curcuminoids. All groups showed 100% mortality at the end of study. | 114 |
| ICR Harlam-Sprague Dawley and C57BL/6 mice (P. berghei ANKA MRA-311/GFP) | 50 mg/kg twice a day | 0–5 | IP/Gavage | IP injection of 25 mg/kg/d Curcumin on day 1–9 p.i. was beneficial in case of PbA GFP infection in ICR mice; no effect was seen in case of PbA/ICR infection. Gavage treatment of PbA infected C57BL/6 prevented CM and delayed death by 10 days, did not change initial parasitemia and no significant effect was seen in ICR mice. |
115 |